Many elderly patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials to treat the kidney cancer—are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open. Analyzing 13 years of data on Medicare patients, the study found that the patients who received targeted therapies were more medically complex than those who received the older, more toxic treatments that were available earlier in the study period, indicating that newer treatments are offering hope to more people.
* This article was originally published here
